Canada Markets close in 5 hrs 23 mins

H-CYTE, Inc. (HCYT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.990.00 (0.00%)
As of 12:43PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close5.99
Open5.99
BidN/A x N/A
AskN/A x N/A
Day's Range5.99 - 5.99
52 Week Range2.02 - 77.00
Volume2
Avg. Volume25
Market Cap978.652M
Beta (5Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-0.04
Earnings DateFeb 23, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days

    Wound Healing and Limb Salvaging Technology Adds to Company’s Asset Portfolio Focused on Unmet Medical NeedsTAMPA, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company has entered into a letter of intent to acquire SkinDisc, a patent pending tissue regeneration technology, that is expected to close within the next 30 days. Highlights: Further supports H-CYTE’s vision to build a diverse asset portfolio and transform i

  • GlobeNewswire

    H-CYTE Completes Acquisition of Jantibody

    Milestone Achieved as Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer Added to Asset PortfolioTAMPA, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company completed the acquisition of Jantibody. Highlights: Jantibody allows H-CYTE to diversify its asset portfolioFocus indication for ovarian cancer with the potential to be used for other diseases such as mesothelioma and pancreatic cance

  • GlobeNewswire

    H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days

    Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset PortfolioTAMPA, Fla., July 22, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company expects to close its acquisition of Jantibody within the next 30 days for an undisclosed amount. Highlights: Milestone achieved as H-CYTE advances plans to build a diverse asset portfolioFocus indication for ovarian cancer with the potential to be use